Source:http://linkedlifedata.com/resource/pubmed/id/15653777
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
2005-1-17
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0098-6151
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
104
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
516; discussion 517; author reply 517
|
| pubmed:dateRevised |
2008-11-21
|
| pubmed:meshHeading |
pubmed-meshheading:15653777-Antipsychotic Agents,
pubmed-meshheading:15653777-Benzodiazepines,
pubmed-meshheading:15653777-Bipolar Disorder,
pubmed-meshheading:15653777-Drug Approval,
pubmed-meshheading:15653777-Humans,
pubmed-meshheading:15653777-United States,
pubmed-meshheading:15653777-United States Food and Drug Administration
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
DO comments on bipolar disorder supplement.
|
| pubmed:publicationType |
Letter,
Comment
|